Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1) (Q36627206)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 December 2015

Language	Label	Description	Also known as
English	Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)	scientific article published on 16 December 2015

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Elżbieta Senkus-Konefka

8

object named as

E Senkus-Konefka

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

M De Santis

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

J Bellmunt

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

C Lucas

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

L Albiges

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

C-C Lin

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A Flechon

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

L Mourey

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

W C Loidl

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

M M Retz

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

N Vaissière

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

S Culine

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

16 December 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

449-454

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

30 September 2017

How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

30 September 2017

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

30 September 2017

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

30 September 2017

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

30 September 2017

Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

30 September 2017

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

30 September 2017

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

30 September 2017

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

30 September 2017

Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

28 June 2018

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

28 June 2018

EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

20 September 2018

Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

20 September 2018

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769994

20 September 2018

Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV609

21 January 2018

Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV609

21 January 2018

Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDV609

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26673352%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36627206&oldid=1956250783"